Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (244) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (29) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (22) Apply Team member filter
- Videos (16) Apply Videos filter
- Webcasts and audio (14) Apply Webcasts and audio filter
- Financial reports (13) Apply Financial reports filter
- Analyst (11) Apply Analyst filter
- Investor contact (5) Apply Investor contact filter
- Event (4) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy g
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy g
Oxford Biomedica notes Homology Medicines’ quarterly report and confirms financials for Oxford Biomedica Solutions LLC are in line with expectations
Oxford, UK – 16 August 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy
Oxford Biomedica signs Licence & Supply Agreement with new partner for LentiVector® platform for late-stage clinical programme
Oxford, UK – 7 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell thera
Oxford Biomedica Solutions signs agreement with new partner for AAV platform
Oxford, UK – 14 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell ther